Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect.
Human monocyte-derived suppressor cells
graft-versus-host disease
graft-versus-leukemia effect
immunosuppressive drugs
inflammation
regulatory T cells
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
19 02 2021
19 02 2021
Historique:
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
29
7
2021
Statut:
epublish
Résumé
Immunosuppressive cell-based therapy is a recent strategy for controlling Graft- The objective of this study was to explore the therapeutic relevance of the HuMoSC in clinical conditions. Immune regulatory functions of HuMoSC were assessed in inflammatory conditions and in the presence of immunosuppressants. The therapeutic efficiency of the association of HuMoSC with immunosuppressants was evaluated in an experimental model of GvHD induced by human PBMC in NOD/SCID/IL2-Rγ Interestingly, the inhibitory functions of HuMoSC against T lymphocytes and their ability to polarize Treg are preserved, HuMoSC-based therapy represents a promising approach for controlling GvHD and could be quickly implemented in clinical practice.
Sections du résumé
Background
Immunosuppressive cell-based therapy is a recent strategy for controlling Graft-
The objective of this study was to explore the therapeutic relevance of the HuMoSC in clinical conditions.
Methods
Immune regulatory functions of HuMoSC were assessed in inflammatory conditions and in the presence of immunosuppressants. The therapeutic efficiency of the association of HuMoSC with immunosuppressants was evaluated in an experimental model of GvHD induced by human PBMC in NOD/SCID/IL2-Rγ
Interestingly, the inhibitory functions of HuMoSC against T lymphocytes and their ability to polarize Treg are preserved,
HuMoSC-based therapy represents a promising approach for controlling GvHD and could be quickly implemented in clinical practice.
Identifiants
pubmed: 33659098
doi: 10.1080/2162402X.2021.1880046
pii: 1880046
pmc: PMC7899641
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1880046Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Am J Transplant. 2013 Dec;13(12):3123-31
pubmed: 24103111
Nat Commun. 2018 Nov 9;9(1):4736
pubmed: 30413714
J Allergy Clin Immunol. 2015 Jun;135(6):1614-24.e4
pubmed: 25630940
Cancer Res. 2010 Jan 1;70(1):99-108
pubmed: 19996287
J Allergy Clin Immunol. 2018 Dec;142(6):1710-1718
pubmed: 30367909
Blood. 2018 Jun 14;131(24):2651-2660
pubmed: 29728401
Stem Cell Rev Rep. 2017 Feb;13(1):104-115
pubmed: 27866327
Stem Cells. 2014 Sep;32(9):2430-42
pubmed: 24805247
Blood. 2015 Sep 24;126(13):1621-8
pubmed: 26265697
Front Immunol. 2017 Dec 14;8:1761
pubmed: 29312302
J Clin Med. 2019 Apr 11;8(4):
pubmed: 30979082
Transpl Immunol. 2012 Aug;27(1):30-8
pubmed: 22613676
Cancer Res. 2006 Jan 15;66(2):1123-31
pubmed: 16424049
Stem Cells. 2016 Sep;34(9):2429-42
pubmed: 27299362
Inflamm Res. 2016 Sep;65(9):679-88
pubmed: 27147271
Bone Marrow Transplant. 2017 Apr;52(4):606-608
pubmed: 27941780
Br J Haematol. 2019 Oct;187(1):25-38
pubmed: 31418827
Nat Med. 2016 Sep;22(9):1013-22
pubmed: 27479084
Clin Sci (Lond). 2019 Nov 15;133(21):2143-2157
pubmed: 31654074
Nat Med. 2014 Jan;20(1):62-8
pubmed: 24362934
Nat Rev Nephrol. 2018 Aug;14(8):493-507
pubmed: 29895977
Haematologica. 2016 Jan;101(1):91-100
pubmed: 26471483
Semin Immunol. 2013 Nov 15;25(4):305-12
pubmed: 24211039
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947
J Exp Med. 2002 Sep 16;196(6):851-7
pubmed: 12235217
J Immunol. 2009 Jun 15;182(12):7963-73
pubmed: 19494321
Int J Cell Biol. 2015;2015:614297
pubmed: 26448755
Immunity. 2003 Jul;19(1):59-70
pubmed: 12871639
Blood. 2019 Nov 7;134(19):1670-1682
pubmed: 31533918
Mol Ther Methods Clin Dev. 2018 Feb 08;9:109-118
pubmed: 29516024
Leukemia. 2008 Jul;22(7):1430-4
pubmed: 18059479